LION bioscience Plans to Sell Its Bioinformatics Business
LION bioscience AG plans the sale of its bioinformatic business. Management board and supervisory board have decided to conduct a structured tender. In the last weeks several companies expressed their interest in LION’s bioinformatics business, especially in LION’s most successful product SRS with world wide distribution. A potential and alternative management buyout has been deferred for the time that the public tender is being put into place.
The assumption is that this process will be started in April and completed within the third quarter of this year.
In this context it is also planned that Dr. Thure Etzold, original inventor of the SRS technology and current CEO of LION, will resign from the board in the near future.
